RecruitingPhase 2NCT06673628
Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients
Studying Angiosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Center, Japan
- Principal Investigator
- Dai Ogata, M.D., Ph.D.
- Intervention
- Pembrolizumab plus Lenvatinib(drug)
- Enrollment
- 38 enrolled
- Eligibility
- 18-85 years · All sexes
- Timeline
- 2024 – 2028
Study locations (5)
- National Cancer Center Hospital East, Kashiwa, Japan
- University Hospital Kyoto Prefectural University of Medicine, Kyoto, Japan
- Nagoya City University Hospital, Nagoya, Japan
- Keio University Hospital, Tokyo, Japan
- National Cancer Center Hospital, Tokyo, Japan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06673628 on ClinicalTrials.govOther trials for Angiosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06898970Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaVarun Monga, MBBS
- RECRUITINGPHASE2NCT07007273Pembrolizumab for Advanced Cutaneous Sarcomas Not Including AngiosarcomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNCT06715579Cardiac Angiosarcoma International RegistryImmune Oncology Research Institute
- RECRUITINGPHASE2NCT06849986IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)Fudan University
- RECRUITINGPHASE1NCT06440005A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid TumorsAngiex, Inc.
- RECRUITINGNCT06375941Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStarsItalian Sarcoma Group
- RECRUITINGNCT06541652A French Multicenter Observational Retrospective Study of Rare Primary Liver CancersFederation Francophone de Cancerologie Digestive
- RECRUITINGPHASE2NCT06277154MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue SarcomaHRYZ Biotech Co.